Aclaris Therapeutics Inc

8AT

Company Profile

  • Business description

    Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

  • Contact

    701 Lee Road
    Suite 103
    WaynePA19087
    USA

    T: +1 484 324-7933

    E: [email protected]

    https://www.aclaristx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    64

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,901.3522.890.29%
DAX 4024,533.7415.82-0.06%
Dow JONES (US)44,458.30217.540.49%
FTSE 1008,956.4989.471.01%
HKSE24,028.37136.050.57%
NASDAQ20,611.34192.870.94%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,263.2637.740.61%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers